GLP-1 Companion Products Market At a Glance Key Growth Drivers, Constraints, and Opportunities Key Factors Driving Growth The soaring popularity of GLP-1 therapies for diabetes and obesity has led to a surge in demand for companion products to augment patient adherence and improve clinical outcomes
Sa prsentation est sous forme liquide dans des flacons unidoses
Discovery work characterised it as roughly 0.4 as active as native GLP-1, 0.3 as active as native glucagon and about 8.9 as active at the GIP receptor [6]
Diarrhea and constipation both occur, sometimes alternating, as gut motility adjusts to the medication
The blockbuster glucagon-like peptide-1 (GLP-1) agonists have emerged as a solution, but costs are a major problem
"In that respect it's maybe a good thing." But Caleb also says the revelation about her need to resort to using GLP-1 medication is slightly "terrifying" and makes them feel "a little bit sad"